Generic CEOs Need To Act Like Brand Execs, Association Head Says
AAM President Davis, a PhRMA veteran, says personal engagement – in addition to lobbying spending – is key to successful policy advocacy.
You may also be interested in...
Incoming Office of Generic Drugs Director Sally Choe is largely unfamiliar to industry, but potentially offers a new perspective.
FDA's Biosimilar Action Plan aims to boost approvals, but Commissioner Gottlieb says he's had a change of heart about how much impact an interchangeability designation can have on market uptake.
Pink Sheet editor and reporters discuss the impact of Francis Collins’ departure as NIH director, whether FDA and CDC COVID-19 messaging should be harmonized, and the narrowing gap between standard and priority assessment costs.